Adverse Drug Reactions in Multi-Drug Resistant Tuberculosis Patients, in India, who had received DOTS Plus Treatment along with Home Care and Counselling

Main Article Content

Joyce Felicia Vaghela

Abstract

Background: Adverse drug reactions are common in MDR-TB patients on treatment. An adverse drug reaction (ADR) is defined as an appreciably harmful or unpleasant reaction resulting from an intervention related to the use of a medicinal product. Revised National Tuberculosis Control Programme used 24-months long Category IV/DOTS Plus regimen for treatment of MDR-TB.


The Community Health Department of St. Stephen’s Hospital started an innovative project in 2009, in the form of Home Care for MDR Patients and it concluded with Long-term Follow-up of patients, who had received DOTS Plus Treatment along with Home Care and Counselling (2015).


Aims: To study the spectrum, severity and the risk factors for ADRs in MDR-TB patients.


Methods: In this retrospective study files of 109 MDR-TB patients who had received treatment along with home care and counselling support, were reviewed. The study was conducted between January to May 2024.


Results: Out of 109 MDR TB patients there were 68 (62%) developed one or more ADR. Joint pains 44(40.36%), was the most commonly observed ADR, followed by nausea 29(26.6%) and vomiting 25(22.93%), weakness 23(21.1%), anxiety and depression 16(14.67%), difficulty in breathing 14(12.84%), tremors 13(11.9%), giddiness 11(10.1%), skin rashes 10(9.2%).


According to Hartwig Scale mild ADRs were 58.8%, moderate 5.9% and severe 35.3%. Patients who had BMI <18.5 experienced less ADRs with an Odds Ratio =0.22; 95% CI=0.06 to 0.72, p=0.0124. Unemployment was associated with higher number of ADRs OR=3.5; 95% CI=0.99 to 12.29, p=0.05.


Sixty-two % MDR TB patients had ADRs. Our treatment outcomes showed 41(60.3) as cured, 24(35.3) died, 2(2.9) defaulted and 1(1.5) failed treatment. This was possible because healthcare teams counselled and provided all possible support to patients 24x7 thus improving adherence to therapy.


Conclusion: ADRs occurred in more than half of the cases, with joint pain being the most common. Interventions such as counselling of patients and their family on importance of adherence to drugs at the initiation of treatment, provision of nutritional support, psychological counselling and motivation, instant referral for ADRs and care of patients at referred facilities, help patients not becoming defaulters.

Keywords: Adverse Drug Reactions, DOTS Plus, Multidrug-Resistant Tuberculosis

Article Details

How to Cite
VAGHELA, Joyce Felicia. Adverse Drug Reactions in Multi-Drug Resistant Tuberculosis Patients, in India, who had received DOTS Plus Treatment along with Home Care and Counselling. Medical Research Archives, [S.l.], v. 12, n. 6, june 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/5309>. Date accessed: 22 july 2024. doi: https://doi.org/10.18103/mra.v12i6.5309.
Section
Research Articles

References

1. Central TB Division Ministry of Health & Family Welfare Government of India. National Tb Elimination Programme. Available at: https://nhm.gov.in/New_Update-2021-22/Presentation/PS-MD-Orientation-workshop-26-08-2021/NTEP.pdf slide 28 [accessed on 10.1.2024]
2. World Health Organization Guidelines for the Programmatic Management of Drug-resistant Tuberculosis: Emergency Update 2008. Available at: WHO/HTM/TB/2008.402. WHO Press, World Health Organization, Geneva. [accessed on 10.1.2024]
3. Prasad R, Gupta N, and Banka A Multidrug-resistant tuberculosis/rifampicin-resistant tuberculosis: Principles of management Lung India. 2018 Jan-Feb; 35(1): 78–81
4. Definitions-and-classification-of-adrs Available at: https://pharmacyinfoline.com/definitions-and-classification-of-adrs/ on [accessed on 14.1.2024]
5. Institute of Medicine (US). Facing the Reality of Drug-Resistant Tuberculosis in India: Challenges and Potential Solutions: Summary of a Joint Workshop by the Institute of Medicine, the Indian National Science Academy, and the Indian Council of Medical Research. Washington (DC): National Academies Press (US); 2012. Available at: https://www.ncbi.nlm.nih.gov/books/NBK92617/ Doi: 10.17226/13243 [accessed on 2.2.2024]
6. Chhabra N, Aseri M.L., Dixit R, et al. Pharmacotherapy for multidrug resistant tuberculosis. J Pharmacology and Pharmacotherapeutics. 2012 Apr-Jun; 3(2): 98–104. Doi: 10.4103/0976-500X.95502
7. Vaghela JF, Kapoor SK, Kumar A, Dass RT, Khanna A, Bhatnagar AK. Home based care to multi-drug resistant tuberculosis patients: A pilot study. Indian Journal of Tuberculosis. 62 (2015) 91-96. Doi: 10.1016/j.ijtb.2015.04.008. PMID: 26117478.
8. Vaghela JF, Anand T. Long-term Follow-up of Multidrug Resistant Tuberculosis Patients of Delhi, who had Received DOTS Plus Treatment along with Home Care and Counselling. Journal of Communicable Diseases - Special Issue on COVID-19. Volume 52, Issue 2 - 2020, Pg. No. 1-7. Doi: 10.24321/0019.5138.202015. License: CC BY-NC 4.0
9. RNTCP DOT Plus Guidelines. 2010. Jan, Available at: http://www.tbcindia.org/pdfs/DOTS_Plus_Guidelines_Jan2010.pdf [Accessed on 10.2.2024].
10. Medscape. Drugs & Diseases. Available at: https://reference.medscape.com/drug/pyrazinamide-342678#4 [Accessed on 16.5.2024]
11. O'Connor, Patel P, Brady MF. National Centre for Biotechnology Information February 16, 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK557617/ [Accessed on 16.5.2024]
12. Vega P, Sweetland A, Acha J, et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004; 8: 749–758. PMID: 15182146
13. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002; 6: 622–627. PMID: 12102302
14. Moore RD, Smith CR, Lietman PS. Risk factors for the development of auditory toxicity in patients receiving aminoglycosides. J Infect Dis. 1984; 149: 23–30. Doi: 10.1093/infdis/149.1.23 . PMID: 6693788
15. Dana E. K, Robb M., Sandra H. L. New Classification and Update on the Quinolone Antibiotics. Am Fam Physician. 2000;61(9):2741-2748. PMID: 10821154
16. Ahmad N, Javaid A, Syed Sulaiman SA, Afridi AK, Zainab, Khan AH. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients. Am J Ther. 2018 Sep/Oct;25(5):e533-e540. Doi: 10.1097/MJT.0000000000000421. PMID: 26938643.
17. Hartwig Scale. Available at: https://in.search.yahoo.com/search?fr=mcafee&type=E210IN826G0&p=Hartwig+scale [Accessed on 20.2.2024]
18. MedCalc Statistical Software version 19.2.6. (MedCalc Software bv, Ostend, Belgium Available at: https://www.medcalc.org/calc/odds_ratio.php [Accessed on 22.02.2024]
19. V.K. Arora, R. Sarin, R Singla et al DOTS-Plus for patients with multidrug-resistant tuberculosis in India: Early results after three years. January 2007. The Indian Journal of Chest Diseases and Allied Sciences. 49:75-79 url={https://api.semanticscholar.org/CorpusID:78374689}
20. Kapadia V, Tripathi S. Diverse drug reactions and outcome analysis of MDR TB patients on dots plus regimen. July 2022. National Journal of Community Medicine 7(1):5-9 Available at: https://njcmindia.com/index.php/file/article/view/843 [Accessed on 26.5.24]
21. Kushemererwa O, Nuwagira E, Kiptoo J, et al. Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda. Available at: SAGE Open Med. 2023 May 3 Doi: 10.1177/20503121231171350. PMID: 37152841; PMCID: PMC10161297 [Accessed on 3.4.2024]
22. Alves C, Mendes D, Marques FB. Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis. Eur J Clin Pharmacol 2019. 75:1431-43. Doi:10.1007/s00228-019-02713-1 [PubMed] [CrossRef] [Google Scholar]
23. Ategyeka PM , Muhoozi M , Naturinda R et al. Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda. BMC Infect Dis. 2023 Mar 10. 23(1):149. Doi: 10.1186/s12879-023-08085-3.
24. Paikray E, Das P, Pattnaik M, Adverse Drug Reaction Monitoring in Multidrug-Resistant Tuberculosis Patients Receiving Bedaquiline and Delamanid-Based Regimen. Available at: Cureus. 2022 Oct; 14(10): e30764. Published online 2022 Oct 27. Doi: 10.7759/cureus.30764 PMCID: PMC9701089. PMID: 36447692 [Accessed on 13.2.2024]
25. Owens RC, Jr, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005;41 Suppl 2: S144-57. 10.1086/428055 [PubMed] [CrossRef] [Google Scholar]
26. Wu S , Zhang Y, Sun F, et al. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis. Available at: https://pubmed.ncbi.nlm.nih.gov/24284652/ [Accessed on 13.2.2024]
27. Drugs and Supplements. Cycloserine (Oral Route). Available at:
28. https://www.mayoclinic.org/drugs-supplements/cycloserine-oral-route/side-effects/drg-20063226 [Accessed on 26.5.2024]
29. Dela AI, Tank ND, Singh AP et al. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four-year retrospective study. Lung India. 2017 Nov-Dec; 34(6): 522–526. Doi: 10.4103/0970-2113.217569
30. WHO. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment (15 June 2020). Available at https://www.who.int/publications/i/item/9789240007048 [Accessed on 25.5.24]
31. World Health Organization. Management of MDR-TB: A Field Guide: A Companion Document to Guidelines for Programmatic Management of Drug-Resistant Tuberculosis: Integrated Management of Adolescent and Adult Illness (IMAI). Geneva: World Health Organization; 2009. Available at: https://www.who.int/publications/i/item/9789241547765 [Accessed on 26.5.2024]
32. Mantefardo B, Sisay G. Case Report: Kanamycin Ototoxicity and MDR-TB Treatment Regimen. Int Med Case Rep J. 2021 (Nov 26) 14:815-817. Doi: 10.2147/IMCRJ.S336259. PMID: 34858067; PMCID: PMC8631973.
33. Chamberlain PD, Sadaka A, Berry S, et al. (2017). Ethambutol optic neuropathy. Current Opinion in Ophthalmology, 28(6), 545-551. Doi:10.1097/ICU.0000000000000416
34. Russom M, Verhamme K M C, Karimi L. et al. Nature, Magnitude and risk factors of adverse drug reactions in multidrug resistant tb patients in Eritrea. Eur Respir J. September 2018. Doi: 10.1183/13993003. congress-2018. PA4746. Conference: ERS International Congress 2018 abstracts. Available at https://www.researchgate.net/publication/329859797_Nature_Magnitude_and_Risk_Factors_of_Adverse_Drug_Reactions_in_Multidrug_Resistant_TB_Patients_in_Eritrea. [Cited on 24.5.2024]
35. Drucker D, Eggo MC, Salit IE et al. Ethionamide-induced goitrous hypothyroidism. Ann Intern Med 1984;100: 837-839. Doi: 10.7326/0003-4819-100-6-837.
36. Park SK, Kim CT, Song SD. Outcome of chemotherapy in107 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. Int J Tuberc Lung Dis 1998 2:877–884. PMID: 9848607
37. International organization for migration tuberculosis working group. Outcome of second line tuberculosis treatment in migrants from Vietnam. Trop Med Int Health. 1998 3:975-980.2 PMID: 9892282
Tahaoglu K, Torun T, Sevim T et al. The treatment of multidrug resistant tuberculosis in Turkey. New England J Med. 2001; 345: 170-174.22. Doi: 10.1056/NEJM200107193450303.